Keyphrases
β-site APP-cleaving Enzyme 1 (BACE1)
100%
Alzheimer's Disease
53%
BACE1 Inhibitor
40%
Protease
37%
Tau Levels
27%
Cerebrospinal Fluid
25%
APH1B
25%
CHL1
25%
Disease Marker
25%
Phospho-tau
25%
L1 Cell Adhesion Molecule (L1CAM)
25%
Therapeutic Target
25%
Human Cerebrospinal Fluid
25%
Healthy Participants
25%
Physiological Function
25%
Alzheimer's Disease Patient
9%
Amyloid Precursor Protein
9%
BACE1 Inhibition
8%
Neurological Disorders
7%
Drug Candidates
6%
Acute Inhibition
6%
Gaps in Knowledge
6%
BACE2
6%
Major Discoveries
6%
Total tau
5%
Protein Level
5%
Phosphorylated tau
5%
Biochemistry, Genetics and Molecular Biology
Protease
56%
Liquid
50%
Tau
37%
CHL1
31%
Enzyme
31%
Amyloid Precursor Protein
31%
Amyloid
31%
Secretase
30%
Growth Cone
25%
Dynamics
25%
Neural Cell Adhesion Molecule
25%
Semaphorin
25%
Genetics
6%
Alzheimer's Disease Clinical Trial
6%
Protein Cerebrospinal Fluid Level
6%
Axon
6%
Mass Spectrometry
6%
Secretome
6%
Cell Adhesion Molecule
6%
Cytoskeleton
6%
Clinical Trial
6%
Cell Culture
6%
Ezrin
6%
Cerebrospinal Fluid Level
6%
Quantitative Proteomics
6%
Protein Catabolism
6%
Mouse
6%
Moesin
6%
Radixin
6%
Cell Death
5%
Pharmacology, Toxicology and Pharmaceutical Science
Alzheimer's Disease
81%
Secretase
37%
Neurologic Disease
25%
Semaphorin 3A
25%
Beta Secretase Inhibitor
25%
Disease Marker
25%
Proteinase
22%
Amyloid
20%
Amyloid Precursor Protein
15%
Enzyme-Linked Immunosorbent Assay
12%
Nerve Degeneration
12%
Side Effect
6%
Radixin
6%
Moesin
6%
Combination Therapy
6%
Ezrin
6%
